Afsaneh Barzi, MD, and Vincent Chung, MD, FACP, answer a question posed by an attendee during a Best of ASCO® Meeting about the role of lenvatinib in the landscape of hepatocellular carcinoma treatment.
Pancreatic cystic neoplasms are categorized using the World Health Organization histologic classification and there are four major subtypes, which have varying malignant potential: serous, mucinous, intraductal papillary mucinous neoplasm, and solid pseudopapillary epithelial neoplasms.
Dr. Flavio G. Rocha reviews liver-directed therapy for advanced intrahepatic cholangiocarcinoma, which can be difficult to manage because of several factors including late diagnosis, early metastatic spread, and potential for liver dysfunction.
Dr. Davendra P. S. Sohal discusses the management of metastatic pancreatic cancer, specifically the advances made since ASCO issued guidelines in 2016 for management of metastatic pancreatic cancer and the future direction for treatment.
Mohamed E. Salem, MD; Ahmed O. Kaseb, MD; and Sunil Krishnan, MD,discuss whether they would consider adding radiation therapy after 6 months of adjuvant capecitabine for a positive microscopic margin in resected biliary tract cancer.
As the worldwide death rate from hepatobiliary cancers continues to grow, Drs. Karasic and Loaiza-Bonilla explain that research must focus on finding an effective treatment—and immunotherapy could be the answer.
Dr. Jorge Gallardo and colleagues discuss the epidemiology of esophageal, gastric, liver, gallbladder, pancreatic, colon, and rectal cancers in Chile and how the country’s changing demographics across the past 20 years have increased cancer mortality rates.